Joshua Lehrer-Graiwer
Keine laufenden Positionen mehr
Vermögen: 3 Mio $ am 30.04.2024
Profil
Joshua Lehrer-Graiwer formerly worked at Graphite Bio, Inc., as President, CEO, CFO, CAO & Director in 2023 and Global Blood Therapeutics, Inc., as Chief Medical Officer from 2019 to 2020.
Dr. Lehrer-Graiwer received his undergraduate degree from Harvard University, graduate degree from the University of Cambridge, and doctorate degree from The University of California, San Francisco.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,65% | 01.02.2024 | 165 953 ( 0,65% ) | 3 Mio $ | 30.04.2024 |
Ehemalige bekannte Positionen von Joshua Lehrer-Graiwer
| Unternehmen | Position | Ende |
|---|---|---|
| LENZ THERAPEUTICS, INC. | Vorstandsvorsitzender | 21.08.2023 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 17.04.2020 |
Ausbildung von Joshua Lehrer-Graiwer
| University of Cambridge | Graduate Degree |
| Harvard University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
